NovellusDx is dedicated to delivering the actionable intelligence that oncologists require to choose the right therapy for each patient. NovellusDx provides comprehensive, fully-automated, functional gene profiling of individual patient tumors including charting the full landscape of known and unknown mutations that drive the cancer’s progression.
By measuring the activity of signaling pathways, NovellusDx’s Funtional Annotation for Cancer Treatment, the FACT system, assess the activity of mutations and combination of mutations and their response to targeted drugs. In addition, the FACT system support biopharma companies throughout the entire life cycle of the drug.
NovellusDx total Funding
NovellusDx latest funding size
Time since last funding
|10 months ago|
|Bio Capital Impact Fund, Windham Venture Partners, Helsinn Group, OrbiMed, InterCure|
When was NovellusDx founded?
NovellusDx was founded in 2012.
Who are NovellusDx key executives?
NovellusDx's key executives are Haim Gil-Ad, Michael Vidne and Gabi Tarcic.
Who are NovellusDx competitors?
Competitors of NovellusDx include UNUM Therapeutics, Biotech Products Services and Research and Artios Pharma.
Where are NovellusDx offices?
NovellusDx has an office in Jerusalem.
How many offices does NovellusDx have?
NovellusDx has 1 office.